Histological features of acute hepatitis after imatinib mesylate treatment. - Wikidata - awgldk - TriplyDB

Histological features of acute hepatitis after imatinib mesylate treatment.

Histological features of acute hepatitis after imatinib mesylate treatment.

http://www.wikidata.org/entity/Q44443460

about

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone.Imatinib-induced fatal acute liver failure Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.Sunitinib-related fulminant hepatic failure: case report and review of the literature.Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report.Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.Dasatinib-induced acute hepatitis.Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.

P2860

Q26749324-43B1F2DF-2367-4AC8-BE84-1A93E92DF6E4 Q26830695-D9C61DBF-8006-4736-96A4-BDEBA9DD5479 Q34710706-80DE80FA-3F0E-4B6C-A6DF-6FD54082EBAB Q36178243-383671E6-7481-41D5-86C8-2A86114CD0A0 Q36654518-EC1CC808-CECD-489D-8A47-17CACF8AAC2D Q37227525-1B777CB8-F65A-4D0C-92D0-19B928CBD243 Q38101884-BEF71289-601D-441A-9EA8-8C207E12F8EF Q38729029-5B5ECEA4-0DE7-4E0D-ACE1-E18CD8B33E02 Q41892625-371D05B4-55DF-4BCA-B8AC-D4D7D7CF3438 Q41896329-AE26FF07-4C69-48E6-9725-AF0B05AA1F67 Q45422025-58C784E2-517A-4F7E-AB9A-4B55010B9AC2 Q46496023-FDF9206A-716E-4C70-9B38-CB9308A497E3 Q53342726-7BEC0B1B-7A2E-41EE-9649-F72ADE3FF1ED

P2860

Histological features of acute hepatitis after imatinib mesylate treatment.

http://www.wikidata.org/entity/Q44443460

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Histological features of acute hepatitis after imatinib mesylate treatment.

@en

Histological features of acute hepatitis after imatinib mesylate treatment.

@nl

type

label

Histological features of acute hepatitis after imatinib mesylate treatment.

@en

Histological features of acute hepatitis after imatinib mesylate treatment.

@nl

prefLabel

Histological features of acute hepatitis after imatinib mesylate treatment.

@en

Histological features of acute hepatitis after imatinib mesylate treatment.

@nl

P1433

Q44443460-606BC46E-0621-4618-B11E-915C37F2181C

P1476

Q44443460-2B04D9C2-6A4B-4BB6-A2A7-22A2F9CCE8D1

P2093

Q44443460-3A82C864-11FD-4BC7-B94E-155C65BC6543

Q44443460-42DED8C9-58E0-4FA4-BF7C-FE616ADDC5B4

Q44443460-BC3ACB1B-20AC-4CD7-900A-2DF5B1368A94

Q44443460-F9C60ABD-B887-44E0-B6ED-E708175FD903

Q44443460-FF653CCC-00D8-4975-834C-5D2484AA52A2

P2860

Q44443460-20693667-5F85-4CA6-919C-09E9A31CE8D0

Q44443460-4DFAC535-5ECC-4835-A53C-337A052E5116

Q44443460-5B2A366D-2F34-48F8-A083-59D8722C8B56

Q44443460-6204879C-66AD-4131-A4C5-66A3BD7BF91D

Q44443460-66EF9FE9-47C0-450C-9606-8E466F832B5A

Q44443460-8CBE2503-F5CA-4635-AE0B-9F553BBA97A8

Q44443460-C1A878ED-A39C-48B3-9006-9AE4E7865F94

Q44443460-FE86D28B-D581-4477-8206-669841875F4A

P2888

Q44443460-A7835408-9E4B-4577-8ACE-47639B3783E4

P304

Q44443460-B8DD1CB0-20F5-4BE2-9E72-12A1ACD05742

P31

Q44443460-2DBC420A-865D-4FF2-9A8C-02B5CE2C739E

P356

Q44443460-C02C6411-849C-465E-9DBE-08EF3B9C4133

P433

Q44443460-03B21492-CD79-4CD6-945E-8D49C4D66B10

P478

Q44443460-94720C01-C546-4DBA-A7BB-70AFBA15A3DD

P577

Q44443460-A9D65171-D921-45CD-9869-0E5783E50A0D

P5875

Q44443460-E84255C3-FFBF-435B-8789-0A885F65C001

P698

Q44443460-D7FA9639-7457-4F00-B161-BAA859DD0A44

P356

P1433

P1476

Histological features of acute hepatitis after imatinib mesylate treatment.

@en

P2093

C James

http://www.w3.org/2001/XMLSchema#string

F-X Mahon

http://www.w3.org/2001/XMLSchema#string

G Marit

http://www.w3.org/2001/XMLSchema#string

H Trouette

http://www.w3.org/2001/XMLSchema#string

P Cony-Makhoul

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Pharmacokinetic drug interactions of macrolides.

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis.

P2888

P304

978-979

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2402910

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10756163

http://www.w3.org/2001/XMLSchema#string

P698

12750713

http://www.w3.org/2001/XMLSchema#string